Challenges in anticancer drug R&D in China

Affiliations

¹ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
² Covance, Shanghai, China.
³ Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Haidian, Beijing, 100142, China.
⁴ Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
⁵ Department of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
⁶ National Center for Drug Evaluation, China Food and Drug Administration, Beijing, China.
⁷ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. Electronic address: zhangli6@mail.sysu.edu.cn.

Shen Zhao et al. Lancet Oncol. 2019 Feb.

. 2019 Feb;20(2):183-186.

doi: 10.1016/S1470-2045(18)30865-9.

¹ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
² Covance, Shanghai, China.
³ Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Haidian, Beijing, 100142, China.
⁴ Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
⁵ Department of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
⁶ National Center for Drug Evaluation, China Food and Drug Administration, Beijing, China.
⁷ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. Electronic address: zhangli6@mail.sysu.edu.cn.

No abstract available

MeSH terms